Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05977998 · ClinicalTrials.gov registry record · Phase 2

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

A Phase 2 study of Gastric Adenocarcinoma and Carcinomatosis, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT05977998: Recruiting Phase 2 study of Gastric Adenocarcinoma and Carcinomatosis, sponsored by M.D. Anderson Cancer Center.

NCT05977998 is a Phase 2 study of Gastric Adenocarcinoma and Carcinomatosis that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants, below the 245-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05977998, a Phase 2 study of Gastric Adenocarcinoma and Carcinomatosis, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

To learn about the effects of paclitaxel and gastrectomy (surgery to remove all or part of the stomach) on improving outcomes in patients with gastric cancer.

Interventions

  • DRUG Paclitaxel
  • DRUG Dexamethasone
  • DRUG Diphenhydramine
  • DRUG Famotidine

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-09-08
Est. Completion 2030-10-31
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What NCT05977998 shows while recruiting

NCT05977998 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 245-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (88% lower).

The record links to 2 conditions, with Gastric Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Paclitaxel is the first listed.

NCT05977998 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05977998 about?

NCT05977998 is a clinical study titled "A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology". To learn about the effects of paclitaxel and gastrectomy (surgery to remove all or part of the stomach) on improving outcomes in patients with gastric cancer.

What is the current status of trial NCT05977998?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-09-08. Estimated completion is 2030-10-31.

What conditions does trial NCT05977998 study?

This clinical trial studies the following conditions: Gastric Adenocarcinoma, Carcinomatosis.

What interventions are being tested in trial NCT05977998?

The interventions under investigation include: Paclitaxel (DRUG), Dexamethasone (DRUG), Diphenhydramine (DRUG), Famotidine (DRUG).

Who is sponsoring clinical trial NCT05977998?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05977998 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastric Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05977998's enrollment target sits among peer trials

30 38th of 47 higher than 9 of 47 other Gastric Adenocarcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Gastric Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05977998, the US trial registry maintained by the National Library of Medicine. NCT05977998 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.